WINT vs CRVS vs NKTR vs AGIO vs PRTA

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Corvus Pharmaceuticals, Inc. (CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +401. 4%, compared to -100. 0% for Windtree Therapeutics, Inc. (WINT). Over 10 years, the gap is even starker: CRVS returned +24. 8% versus WINT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.

96β versus Windtree Therapeutics, Inc. 's 2. 25β — meaning WINT is approximately 135% more volatile than PRTA relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Windtree Therapeutics, Inc. grew EPS 97. 8% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corvus Pharmaceuticals, Inc.

(CRVS) is the more profitable company, earning 0. 0% net margin versus -454. 0% for Windtree Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRVS leads at 0. 0% versus -151. 3% for WINT. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CRVS: 127.

3% to $33. 17.

In this comparison, WINT (100.

0% yield) pays a dividend. CRVS, NKTR, AGIO, PRTA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

96)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRTA: -72. 5%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: WINT is a small-cap income-oriented stock; CRVS is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock. WINT pays a dividend while CRVS, NKTR, AGIO, PRTA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.